IPSC insider trading
HealthcareCentury Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Century Therapeutics, Inc.
Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Company website: www.centurytx.com
IPSC insider activity at a glance
FilingIQ has scored 126 insider transactions for IPSC since Jun 22, 2021. The most recent filing in our index is dated May 4, 2026.
Across the full history, 7 open-market purchases
and 54 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on IPSC insider trades is 55.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
13F funds holding IPSC
Frequently asked
- How many insider trades does FilingIQ track for IPSC?
- FilingIQ tracks 126 Form 4 insider transactions for IPSC (Century Therapeutics, Inc.), covering filings from Jun 22, 2021 onwards. 9 of those were filed in the last 90 days.
- Are IPSC insiders net buyers or net sellers?
- Across the full Form 4 history for IPSC, 7 transactions (6%) were open-market purchases and 54 (43%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does IPSC insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is IPSC in?
- Century Therapeutics, Inc. (IPSC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $161.26M.
Methodology & sources
Every IPSC insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.